INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY)/, Wednesday announced a collaboration with Walmart Inc. (WMT) to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect.
Starting mid-November, Zepbound single-dose vials will be available in all approved strengths, with the lowest dose starting at $349 per month with self-pay, at Walmart pharmacies nationwide.
Notably, the collaboration with Walmart expands convenient access to Zepbound, especially for those who prefer the ease of pickup at their local Walmart pharmacy.
In the pre-market hours, LLY is trading at $826.50, up 0.74 percent on the New York Stock Exchange.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
